Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | EGL-001 |
Trade Name | |
Synonyms | EGL 001|EGL001 |
Drug Descriptions |
EGL-001 is an immunocytokine comprising an anti-CTLA-4 IgG1 linked to an IL-2 mutein that binds to IL2RA (CD25) expressed on T-regulatory cells, potentially resulting in decreased IL2RA-mediated signaling, reduced immunosuppression, and enhanced antitumor activity (Cancer Res (2024) 84 (6_Supplement): 4079). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
EGL-001 | EGL-001 | 0 | 1 |
EGL-001 + unspecified PD-L1 antibody | EGL-001 unspecified PD-L1 antibody | 0 | 1 |